Literature DB >> 19189036

Responsiveness of the electronic Personal Assessment Questionnaire-Pelvic Floor (ePAQ-PF).

G L Jones1, S C Radley, J Lumb, A Farkas.   

Abstract

This study aimed to evaluate the responsiveness of the electronic Personal Assessment Questionnaire-Pelvic Floor (ePAQ-PF) in women undergoing surgery for pelvic floor disorders. Fifty-four women undergoing tension-free vaginal tape (TVT) and 47 women undergoing prolapse surgery completed ePAQ-PF at baseline and 3 months postoperatively. Responsiveness was calculated using effect sizes, standardized response means, responsiveness statistic, and minimally important difference. In the TVT group, the largest effect sizes were seen in the urinary domains for stress urinary incontinence (2.4), quality of life (2.2), and overactive bladder (0.9). In the prolapse group, the largest effect sizes were seen in the vaginal domains for prolapse (2.1) and quality of life (1.0). ePAQ-PF is responsive to change in women undergoing TVT or prolapse surgery in the salient and expected domains of stress incontinence and prolapse and quality of life and can be recommended for outcome measurement in this context.

Entities:  

Mesh:

Year:  2009        PMID: 19189036     DOI: 10.1007/s00192-008-0790-9

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  25 in total

1.  Computer interviewing in urogynaecology: concept, development and psychometric testing of an electronic pelvic floor assessment questionnaire in primary and secondary care.

Authors:  S C Radley; G L Jones; E A Tanguy; V G Stevens; C Nelson; N J Mathers
Journal:  BJOG       Date:  2006-02       Impact factor: 6.531

2.  Electronic pelvic floor symptoms assessment: tests of data quality of ePAQ-PF.

Authors:  G L Jones; S C Radley; J Lumb; S Jha
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06-14

Review 3.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

4.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

Authors:  E F Juniper; G H Guyatt; A Willan; L E Griffith
Journal:  J Clin Epidemiol       Date:  1994-01       Impact factor: 6.437

Review 5.  Methods to explain the clinical significance of health status measures.

Authors:  Gordon H Guyatt; David Osoba; Albert W Wu; Kathleen W Wyrwich; Geoffrey R Norman
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

6.  Does sexual function change after surgery for stress urinary incontinence and/or pelvic organ prolapse? A multicenter prospective study.

Authors:  Rebecca G Rogers; Dorothy Kammerer-Doak; Amy Darrow; Kristen Murray; Clifford Qualls; Ambre Olsen; Matthew Barber
Journal:  Am J Obstet Gynecol       Date:  2006-11       Impact factor: 8.661

7.  Prevalence of urinary and fecal incontinence and symptoms of genital prolapse in women.

Authors:  Uustal Fornell Eva; Wingren Gun; Kjølhede Preben
Journal:  Acta Obstet Gynecol Scand       Date:  2003-03       Impact factor: 3.636

8.  Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence.

Authors:  Karen Ward; Paul Hilton
Journal:  BMJ       Date:  2002-07-13

9.  Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice.

Authors:  G Ghoniem; E Stanford; K Kenton; C Achtari; R Goldberg; T Mascarenhas; M Parekh; K Tamussino; S Tosson; G Lose; E Petri
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-11-17

10.  What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D.

Authors:  Stephen J Walters; John E Brazier
Journal:  Health Qual Life Outcomes       Date:  2003-04-11       Impact factor: 3.186

View more
  7 in total

1.  The effect of posterior colporrhaphy on anorectal function.

Authors:  Anupreet Dua; Stephen Radley; Steven Brown; Swati Jha; Georgina Jones
Journal:  Int Urogynecol J       Date:  2011-11-24       Impact factor: 2.894

2.  Effect of anticholinergics on the overactive bladder and bowel domain of the electronic personal assessment questionnaire (ePAQ).

Authors:  S Bulchandani; P Toozs-Hobson; M Parsons; S McCooty; K Perkins; P Latthe
Journal:  Int Urogynecol J       Date:  2014-10-17       Impact factor: 2.894

3.  The personal impact of pelvic floor symptoms and their relationship to age.

Authors:  Anupreet Dua; Stephen Radley; Georgina Jones; Andrew Farkas
Journal:  Int Urogynecol J       Date:  2013-07-23       Impact factor: 2.894

4.  Health status of COPD patients undergoing pulmonary rehabilitation: A comparative responsiveness of the CAT and SGRQ.

Authors:  Anabel Sciriha; Stephen Lungaro-Mifsud; Josianne Scerri; Rosalie Magro; Liberato Camilleri; Stephen Montefort
Journal:  Chron Respir Dis       Date:  2017-03-15       Impact factor: 2.444

Review 5.  How is pain associated with pelvic mesh implants measured? Refinement of the construct and a scoping review of current assessment tools.

Authors:  Jennifer Todd; Jane E Aspell; Michael C Lee; Nikesh Thiruchelvam
Journal:  BMC Womens Health       Date:  2022-09-30       Impact factor: 2.742

6.  The impact of surgery for vulval cancer upon health-related quality of life and pelvic floor outcomes during the first year of treatment: a longitudinal, mixed methods study.

Authors:  Georgina L Jones; Richard M Jacques; Joanne Thompson; Hilary J Wood; Jane Hughes; William Ledger; Mo'iad Alazzam; Stephen C Radley; John A Tidy
Journal:  Psychooncology       Date:  2015-09-25       Impact factor: 3.894

7.  Evaluating the impact of a 'virtual clinic' on patient experience, personal and provider costs of care in urinary incontinence: A randomised controlled trial.

Authors:  Georgina Jones; Victoria Brennan; Richard Jacques; Hilary Wood; Simon Dixon; Stephen Radley
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.